COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy (CoMPACT) is an ongoing clinical trial focused on improving treatments for treatment-resistant depression (TRD). Major depressive disorder (MDD) affects a third of the world population, and up to 30% of those patients develop TRD, where conventional therapies fail to provide relief, leading to prolonged disability and reduced quality of life.

CoMPACT explores a novel, personalized approach to repetitive transcranial magnetic stimulation (rTMS), a technique shown to benefit patients who do not respond to standard treatments. The trial tests an accelerated, high-frequency burst rTMS protocol that delivers multiple stimulation sessions each day over several days. Both targeting and dosing are based on individual brain scans to personalize and optimize treatment effects. The primary target for stimulation is the dorsolateral prefrontal cortex (DLPFC), but the trial also explores the effect of stimulating the left inferior parietal lobule (IPL), as part of its innovative approach. Through advanced brain mapping (including EEG and fMRI), CoMPACT aims to identify brain networks and biomarkers that can predict how patients will respond to treatment, paving the way for more personalized and effective therapies for treatment-resistant depression.

The CoMPACT project is a collaboration between the Center for Neuropsychiatric Depression Research (CNDR), Mental Health Centre North Zealand, DTU Health Tech, and DRCMR. It is funded 4.4 million by the Independent Research Fund Denmark (PI: Prof. Poul Videbech) and builds on technologies developed in the Grand Solutions project "Precision Brain-Circuit-Therapy" (PI: Prof. Hartwig Siebner).